Bill No. CS for CS for SB 2354

Amendment No. ____ CHAMBER ACTION Senate House 1 2 3 4 5 6 7 8 9 10 Senator Diaz-Balart moved the following amendment: 11 12 13 Senate Amendment (with title amendment) On page 66, between lines 27 and 28, 14 15 16 insert: 17 Section 26. Florida Commission on Excellence in Health 18 Care.--19 (1) LEGISLATIVE FINDINGS AND INTENT.--The Legislature 20 finds that the health care delivery industry is one of the largest and most complex industries in Florida. The 21 22 Legislature finds that additional focus on strengthening health care delivery systems by eliminating avoidable mistakes 23 24 in the diagnosis and treatment of Floridians holds tremendous 25 promise to increase the quality of health care services 26 available to Floridians. To achieve this enhanced focus, it is 27 the intent of the Legislature to create the Florida Commission on Excellence in Health Care to facilitate the development of 28 29 a comprehensive statewide strategy for improving health care 30 delivery systems through meaningful reporting standards, data collection and review, and quality measurement. 31 1

8:10 PM 05/01/00

Bill No. CS for CS for SB 2354

Amendment No. ____

_	
1	(2) DEFINITIONSAs used in this act, the term:
2	(a) "Agency" means the Agency for Health Care
3	Administration.
4	(b) "Commission" means the Florida Commission on
5	Excellence in Health Care.
6	(c) "Department" means the Department of Health.
7	(d) "Error," with respect to health care, means an
8	unintended act, by omission or commission.
9	(e) "Health care practitioner" means any person
10	licensed under chapter 457; chapter 458; chapter 459; chapter
11	460; chapter 461; chapter 462; chapter 463; chapter 464;
12	chapter 465; chapter 466; chapter 467; part I, part II, part
13	III, part V, part X, part XIII, or part XIV of chapter 468;
14	chapter 478; chapter 480; part III or part IV of chapter 483;
15	chapter 484; chapter 486; chapter 490; or chapter 491, Florida
16	Statutes.
17	(f) "Health care provider" means any health care
18	facility or other health care organization licensed or
19	certified to provide approved medical and allied health
20	services in this state.
21	(3) COMMISSION; DUTIES AND RESPONSIBILITIESThere is
22	created the Florida Commission on Excellence in Health Care.
23	The commission shall:
24	(a) Identify existing data sources that evaluate
25	quality of care in Florida and collect, analyze, and evaluate
26	this data.
27	(b) Establish guidelines for data sharing and
28	coordination.
29	(c) Identify core sets of quality measures for
30	standardized reporting by appropriate components of the health
31	care continuum.
	2 8:10 PM 05/01/00 2 s2354c2c-37k0a

1	(d) Recommend a framework for quality measurement and
2	outcome reporting.
3	(e) Develop quality measures that enhance and improve
4	the ability to evaluate and improve care.
5	(f) Make recommendations regarding research and
6	development needed to advance quality measurement and
7	reporting.
8	(g) Evaluate regulatory issues relating to the
9	pharmacy profession and recommend changes necessary to
10	optimize patient safety.
11	(h) Facilitate open discussion of a process to ensure
12	that comparative information on health care quality is valid,
13	reliable, comprehensive, understandable, and widely available
14	in the public domain.
15	(i) Sponsor public hearings to share information and
16	expertise, identify "best practices," and recommend methods to
17	promote their acceptance.
17 18	promote their acceptance. (j) Evaluate current regulatory programs to determine
18	(j) Evaluate current regulatory programs to determine
18 19	(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient
18 19 20	(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety.
18 19 20 21	(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing
18 19 20 21 22	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and</pre>
18 19 20 21 22 23	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient</pre>
18 19 20 21 22 23 24	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient safety.</pre>
18 19 20 21 22 23 24 25	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient safety. (1) Analyze how effective existing regulatory systems</pre>
18 19 20 21 22 23 24 25 26	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient safety. (1) Analyze how effective existing regulatory systems are in ensuring continuous competence and knowledge of</pre>
 18 19 20 21 22 23 24 25 26 27 	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient safety. (1) Analyze how effective existing regulatory systems are in ensuring continuous competence and knowledge of effective safety practices.</pre>
18 19 20 21 22 23 24 25 26 27 28	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient safety. (1) Analyze how effective existing regulatory systems are in ensuring continuous competence and knowledge of effective safety practices. (m) Develop a framework for organizations that</pre>
 18 19 20 21 22 23 24 25 26 27 28 29 	<pre>(j) Evaluate current regulatory programs to determine what changes, if any, need to be made to facilitate patient safety. (k) Review public and private health care purchasing systems to determine if there are sufficient mandates and incentives to facilitate continuous improvement in patient safety. (l) Analyze how effective existing regulatory systems are in ensuring continuous competence and knowledge of effective safety practices. (m) Develop a framework for organizations that license, accredit, or credential health care practitioners and</pre>

necessary to remove the unsafe provider or practitioner from 1 2 practice or operation until such time as the practitioner or 3 provider has proven safe to practice or operate. 4 (n) Recommend procedures for development of a 5 curriculum on patient safety and methods of incorporating such 6 curriculum into training, licensure, and certification 7 requirements. (o) Develop a framework for regulatory bodies to 8 9 disseminate information on patient safety to health care 10 practitioners, health care providers, and consumers through conferences, journal articles and editorials, newsletters, 11 12 publications, and Internet websites. (p) Recommend procedures to incorporate recognized 13 14 patient safety considerations into practice guidelines and 15 into standards related to the introduction and diffusion of new technologies, therapies, and drugs. 16 17 (q) Recommend a framework for development of 18 community-based collaborative initiatives for error reporting and analysis and implementation of patient safety 19 20 improvements. 21 (r) Evaluate the role of advertising in promoting or 22 adversely affecting patient safety. (4) MEMBERSHIP, ORGANIZATION, MEETINGS, PROCEDURES, 23 24 STAFF.--25 (a) The commission shall consist of: 1. The Secretary of Health and the Director of Health 26 27 Care Administration; 2. One representative each from the following agencies 28 29 or organizations: the Board of Medicine, the Board of 30 Osteopathic Medicine, the Board of Pharmacy, the Board of 31 Dentistry, the Board of Nursing, the Florida Dental 4 8:10 PM 05/01/00

-	
1	Association, the Florida Medical Association, the Florida
2	Osteopathic Medical Association, the Florida Chiropractic
3	Association, the Florida Chiropractic Society, the Florida
4	Podiatric Medical Association, the Florida Nurses Association,
5	the Florida Organization of Nursing Executives, the Florida
б	Pharmacy Association, the Florida Society of Health System
7	Pharmacists, Inc., the Florida Hospital Association, the
8	Association of Community Hospitals and Health Systems of
9	Florida, Inc., the Florida League of Health Systems, the
10	Florida Health Care Risk Management Advisory Council, the
11	Florida Health Care Association, the Florida Statutory
12	Teaching Hospital Council, Inc., the Florida Statutory Rural
13	Hospital Council, the Florida Association of Homes for the
14	Aging, and the Florida Society for Respiratory Care;
15	3. Two health lawyers, appointed by the Secretary of
16	Health, one of whom must be a member of the Health Law Section
17	of The Florida Bar who defends physicians and one of whom must
18	be a member of the Academy of Florida Trial Lawyers;
19	4. Two representatives of the health insurance
20	industry, appointed by the Director of Health Care
21	Administration, one of whom shall represent indemnity plans
22	and one of whom shall represent managed care;
23	5. Five consumer advocates, consisting of one from the
24	Association for Responsible Medicine, two appointed by the
25	Governor, one appointed by the President of the Senate, and
26	one appointed by the Speaker of the House of Representatives;
27	6. Two legislators, one appointed by the President of
28	the Senate and one appointed by the Speaker of the House of
29	Representatives; and
30	7. One representative of a Florida medical school
31	appointed by the Secretary of Health.
	5 8:10 PM 05/01/00 5 82354c2c-37k0a

8:10 PM 05/01/00

Bill No. <u>CS for CS for SB 2354</u>

Amendment No. ____

1 2 Commission membership shall reflect the geographic and 3 demographic diversity of the state. 4 (b) The Secretary of Health and the Director of Health 5 Care Administration shall jointly chair the commission. 6 Subcommittees shall be formed by the joint chairs, as needed, 7 to make recommendations to the full commission on the subjects assigned. However, all votes on work products of the 8 commission shall be at the full commission level, and all 9 10 recommendations to the Governor, the President of the Senate, 11 and the Speaker of the House of Representatives must pass by a 12 two-thirds vote of the full commission. Sponsoring agencies 13 and organizations may designate an alternative member who may attend and vote on behalf of the sponsoring agency or 14 15 organization in the event the appointed member is unable to 16 attend a meeting of the commission or any subcommittee. The 17 commission shall be staffed by employees of the Department of 18 Health and the Agency for Health Care Administration. Sponsoring agencies or organizations must fund the travel and 19 related expenses of their appointed members on the commission. 20 21 Travel and related expenses for the consumer members of the commission shall be reimbursed by the state pursuant to 22 section 112.061, Florida Statutes. The commission shall hold 23 24 its first meeting no later than July 15, 2000. 25 (5) EVIDENTIARY PROHIBITIONS.--(a) The findings, recommendations, evaluations, 26 27 opinions, investigations, proceedings, records, reports, 28 minutes, testimony, correspondence, work product, and actions of the commission shall be available to the public, but may 29 not be introduced into evidence at any civil, criminal, 30 special, or administrative proceeding against a health care 31

8:10 PM 05/01/00

practitioner or health care provider arising out of the 1 matters which are the subject of the findings of the 2 3 commission. Moreover, no member of the commission shall be 4 examined in any civil, criminal, special, or administrative 5 proceeding against a health care practitioner or health care provider as to any evidence or other matters produced or б 7 presented during the proceedings of this commission or as to any findings, recommendations, evaluations, opinions, 8 investigations, proceedings, records, reports, minutes, 9 10 testimony, correspondence, work product, or other actions of 11 the commission or any members thereof. However, nothing in 12 this section shall be construed to mean that information, 13 documents, or records otherwise available and obtained from original sources are immune from discovery or use in any 14 15 civil, criminal, special, or administrative proceeding merely 16 because they were presented during proceedings of the 17 commission. Nor shall any person who testifies before the 18 commission or who is a member of the commission be prevented from testifying as to matters within his or her knowledge in a 19 subsequent civil, criminal, special, or administrative 20 21 proceeding merely because such person testified in front of 22 the commission. (b) The findings, recommendations, evaluations, 23 opinions, investigations, proceedings, records, reports, 24 minutes, testimony, correspondence, work product, and actions 25 of the commission shall be used as a guide and resource and 26 27 shall not be construed as establishing or advocating the standard of care for health care practitioners or health care 28 providers unless subsequently enacted into law or adopted in 29 30 rule. Nor shall any findings, recommendations, evaluations, opinions, investigations, proceedings, records, reports, 31

8:10 PM 05/01/00

minutes, testimony, correspondence, work product, or actions 1 of the commission be admissible as evidence in any way, 2 3 directly or indirectly, by introduction of documents or as a 4 basis of an expert opinion as to the standard of care 5 applicable to health care practitioners or health care providers in any civil, criminal, special, or administrative б 7 proceeding unless subsequently enacted into law or adopted in 8 rule. (c) No person who testifies before the commission or 9 10 who is a member of the commission may specifically identify any patient, health care practitioner, or health care provider 11 12 by name. Moreover, the findings, recommendations, evaluations, opinions, investigations, proceedings, records, reports, 13 minutes, testimony, correspondence, work product, and actions 14 15 of the commission may not specifically identify any patient, 16 health care practitioner, or health care provider by name. 17 (6) REPORT; TERMINATION. -- The commission shall provide 18 a report of its findings and recommendations to the Governor, the President of the Senate, and the Speaker of the House of 19 Representatives no later than February 1, 2001. After 20 submission of the report, the commission shall continue to 21 exist for the purpose of assisting the Department of Health, 22 the Agency for Health Care Administration, and the regulatory 23 24 boards in their drafting of proposed legislation and rules to 25 implement its recommendations and for the purpose of providing information to the health care industry on its 26 27 recommendations. The commission shall be terminated June 1, 28 2001. 29 Section 27. The sum of \$91,000 in nonrecurring general 30 revenue is hereby appropriated from the General Revenue Fund to the Department of Health to cover costs of the Florida 31 8

8:10 PM 05/01/00

Commission on Excellence in Health Care relating to the travel 1 and related expenses of staff and consumer members and the 2 3 reproduction and dissemination of documents. 4 5 (Redesignate subsequent sections.) 6 7 8 9 And the title is amended as follows: 10 On page 5, line 2, after the semicolon, 11 12 insert: 13 creating the Florida Commission on Excellence 14 in Health Care; providing legislative findings and intent; providing definitions; providing 15 16 duties and responsibilities; providing for 17 membership, organization, meetings, procedures, and staff; providing for reimbursement of 18 travel and related expenses of certain members; 19 20 providing certain evidentiary prohibitions; 21 requiring a report to the Governor, the President of the Senate, and the Speaker of the 22 House of Representatives; providing for 23 24 termination of the commission; providing an 25 appropriation; 26 27 28 29 30 31

8:10 PM 05/01/00